SARS-CoV-2 vaccination for patients with inflammatory bowel diseases: recommendations from an international consensus meeting.
SARS-CoV-2 vaccination for patients with inflammatory bowel diseases: recommendations from an international consensus meeting.
复制标题
DOI：
10.1136/gutjnl-2020-324000
复制
发表时间：
2021-04
期刊：
影响因子：
24.5
通讯作者：
International Organization for the Study of Inflammatory Bowel Diseases (IOIBD)
中科院分区：
文献类型：
--
作者：
Siegel CA;Melmed GY;McGovern DP;Rai V;Krammer F;Rubin DT;Abreu MT;Dubinsky MC;International Organization for the Study of Inflammatory Bowel Disease (IOIBD);International Organization for the Study of Inflammatory Bowel Diseases (IOIBD)
背景新冠肺炎大流行已经夺走了全球近200万人的生命。1随着SARS-CoV-2的快速测序，制药公司和学术机构在各种现有的和新的疫苗平台的支持下迅速产生了候选疫苗。2-4疫苗以前所未有的速度加速进入第三阶段开发，2020年12月，两种信使核糖核酸疫苗和一种灭活疫苗获准在一些国家使用。其他疫苗平台和候选疫苗正处于第三阶段测试的后期阶段。5疫苗接种的优先次序通常由地区卫生当局根据接触SARS-CoV-2的风险和发生新冠肺炎并发症的风险确定，以公平地保护和促进全球公众福祉。6-8
BackgroundThe COVID-19 pandemic has claimed the lives of nearly 2 million people worldwide. 1 Following rapid sequencing of SARS-CoV-2, pharmaceutical companies and academic institutions rapidly generated vaccine candidates on the back of a variety of both established and novel vaccine platforms. 2–4 Vaccines accelerated at unprecedented pace to phase 3 development, and in December 2020, two mRNA vaccines and one inactivated vaccine were authorised for use in a number of countries. Additional vaccine platforms and candidates are in late stages of phase 3 testing. 5 Prioritisation of vaccine access is generally determined by regional health authorities on the basis of risk of SARS-CoV-2 exposure and risk of developing complications from COVID-19 in order to equitably protect and promote global public well-being. 6–8
登录
查看更多内容
BNT162B2 mRNA COVID-19疫苗的安全性和功效。
DOI：
10.1056/nejmoa2034577
发表时间：
2020-12-31
期刊：
The New England journal of medicine
影响因子：
--
作者：
Polack FP;Thomas SJ;Kitchin N;Absalon J;Gurtman A;Lockhart S;Perez JL;Pérez Marc G;Moreira ED;Zerbini C;Bailey R;Swanson KA;Roychoudhury S;Koury K;Li P;Kalina WV;Cooper D;Frenck RW Jr;Hammitt LL;Türeci Ö;Nell H;Schaefer A;Ünal S;Tresnan DB;Mather S;Dormitzer PR;Şahin U;Jansen KU;Gruber WC;C4591001 Clinical Trial Group
通讯作者：
C4591001 Clinical Trial Group
影响因子：
32.4
作者：
Ni, Ling;Ye, Fang;Dong, Chen
通讯作者：
Dong, Chen
DOI：
10.1016/j.cgh.2020.08.003
发表时间：
2020-11
期刊：
Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association
影响因子：
--
作者：
D'Amico F;Danese S;Peyrin-Biroulet L
通讯作者：
Peyrin-Biroulet L
影响因子：
4.9
作者：
deBruyn, Jennifer;Fonseca, Kevin;Wrobel, Iwona
通讯作者：
Wrobel, Iwona
影响因子：
4.9
作者：
deBruyn, Jennifer C. C.;Hilsden, Robert;Wrobel, Iwona
通讯作者：
Wrobel, Iwona